Q-omics provides the consensus-scored MARK2P8 profile across patient tissues and cancer cell-line models. MARK2P8 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MARK2P8 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, MARK2P8 RNA expression shows 15,349 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, THCA, and THYM as cancer lineages where MARK2P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARK2P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARK2P8 survival associations across molecular data types. MARK2P8 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARK2P8 RNA expression–survival associations across cancer types. High MARK2P8 expression shows unfavorable associations in ACC, LGG and UCEC, but favorable associations in UCS, BRCA and COAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for MARK2P8 RNA expression.
This table summarizes MARK2P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MARK2P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARK2P8 shows lower tumor expression in THCA and BRCA and higher tumor expression in KIRC, CHOL, HNSC and COAD. The THCA box plot shows higher MARK2P8 RNA expression in normal versus tumor tissue (log2 FC = −0.101, t-test p < 0.001).
This table shows molecular features associated with MARK2P8 in patient tissues and cancer cell lines. In patient samples, MARK2P8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
